Navigation Links
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Date:9/18/2008

ive infections until infections are controlled. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections.

If latent tuberculosis is diagnosed, appropriate treatment for latent tuberculosis must be initiated with anti-tuberculosis prophylaxis therapy before starting treatment with HUMIRA, and in accordance with local recommendations. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infection or with underlying conditions that may predispose patients to infections.

TNF-blocking agents have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of the virus. Some cases have been fatal. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating HUMIRA.

The combination of HUMIRA and anakinra and HUMIRA and abatacept is not recommended.

TNF antagonists, including HUMIRA, have been associated in rare cases with demyelinating disease including multiple sclerosis, Guillain-Barre syndrome and optic neuritis, and serious allergic reactions. Rare reports of pancytopenia including aplastic anemia have been reported with TNF-blocking agents. Adverse events of the haematologic system, including medically significant cytopenia have been infrequently reported with HUMIRA.

More cases of malignancies including lymphoma have been observed among patients receiving a TNF antagonist compared with control patients in clinical trials. The size of the control group and limited duration of the controlled portions of studies precludes the ability to draw firm conclusions.

Furthermore, there is an increased background lymphoma risk in rheumatoid arthritis p
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
6. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
11. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Cardinal Health today announced the launch of its new ... increase efficiencies and minimize waste in acute drainage, biopsy ... trays include the essential clinical supplies needed for each ... organizing supplies for procedures and the amount of waste ...
... Pharmaceuticals International, Inc. (NYSE: VRX ... acquired Probiotica Laboratorios Ltda., a leader in sports ... markets a full line of over-the-counter sports nutrition ... percent share of the market. Valeant will acquire ...
Cached Medicine Technology:Cardinal Health Introduces Diagnostic Procedure Trays 2Valeant Pharmaceuticals Acquires Probiotica in Brazil 2
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... the age of forty with breast cancer who are given ... chemotherapy, may not be benefiting from these drugs. This is ... hormones such as estrogen, according to research published in the ... a young age is very worrying in terms of survival," ...
... Benefit, MARYSVILLE, Calif., Oct. 10 Yuba County ... filing of a,formal grievance over the county,s refusal to ... year. Because of the county,s unwillingness to abide ... elderly or have disabilities must play,a waiting game with ...
... Pa., Oct. 10 The following is,being issued by the Pennsylvania Breast Cancer Coalition:, WHAT: ... of the Pennsylvania Breast ... two-day event, held every October, is the premiere breast ... thousand attendees participate ...
... key protein that controls how stem cells choose to ... smooth muscle cells that support blood vessels, according to ... National Academy of Sciences (PNAS). The results not ... in the human fetus, but also suggest new ways ...
... (pronounced,zy-ince), one of the fastest growing brands in the ... has received access,to up to $12 million in a ... intends to use a significant portion of the,investment to ... Xenergy is a combination of Zen and Energy and ...
... say , WEDNESDAY, Oct. 10 (HealthDay News) -- Adult stem ... stem cells in an undifferentiated state, U.S. researchers report. , ... change into any kind of cell is regulated differently in ... also challenges findings from more than 50 studies that concluded ...
Cached Medicine News:Health News:Cancer conflict with chemotherapy treatment 2Health News:Caregivers Demand County Honor Their Contract 2Health News:PA Breast Cancer Coalition Announces Special Press Availability for PA Breast Cancer Coalition Annual Conference 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5Health News:XYIENCE(R) Announces $12 Million Funding and Signing of Long Term UFC(R) Sponsorship 2Health News:Study Probes Difference Between Embryonic, Adult Stem Cells 2
... Single Use linear stapler with ... Auto Suture™ PREMIUM POLY CS™-57 disposable ... creation of a temporary opening, such ... cesarean section, or when transecting muscle ...
... Use reloadable linear stapler ... (DST™) titanium staples., ... Reloadable staplers has application ... and thoracic surgical procedures ...
... reloadable linear stapler for resection, transection and ... Suture™ MULTIFIRE GIA™ 60 and 80 single ... and 80 single use loading units and ... single use surgical stapler with MULTIFIRE SGIA™ ...
... With Titanium Staples for use with PI™ ... ,The PI™ disposable stapler is designed ... of normal, healthy internal tissues. The instrument ... staggered row, when using the 30 VASCULAR ...
Medicine Products: